HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

5,7-dichlorokynurenic acid

potent antagonist at the N-methyl-D-aspartate receptor-associated glycine binding site

Also Known As:

5,7-DCKA; 5,7-dichloroquinurenic acid

Networked: 6 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - Hydroxyquinolines: 9
        Kynurenic Acid: 693
        5,7-dichlorokynurenic acid: 6
- Heterocyclic Acids
  - Xanthurenates
    - Kynurenic Acid: 693
      - 5,7-dichlorokynurenic acid: 6

Experts

1.	Chizh, Boris A: 1 article (06/2005)
2.	Christoph, Thomas: 1 article (06/2005)
3.	Englberger, Werner: 1 article (06/2005)
4.	Reissmüller, Elke: 1 article (06/2005)
5.	Schiene, Klaus: 1 article (06/2005)
6.	Senra-Vidal, A: 1 article (01/2001)
7.	Sierra-Marcuño, G: 1 article (01/2001)
8.	Sierra-Paredes, G: 1 article (01/2001)
9.	Frankiewicz, T: 1 article (02/2000)
10.	Parsons, C G: 1 article (02/2000)

Related Diseases

1.	Muscle Rigidity 05/18/1998 - "5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG). " 01/01/1998 - "AP-5 (2 and 5 micrograms/0.5 microliter), a competitive antagonist of the NMDA receptor, and 5,7-dichlorokynurenic acid (1.0-4.5 micrograms/0.5 microliter), the glycine site antagonist injected bilaterally into the rostral striatum, inhibited the muscle rigidity induced by haloperidol. "
2.	Ganglion Cysts (Ganglion) 06/01/1995 - "However, 5,7-dichlorokynurenic acid (5,7-DCK), an antagonist for the glycine site on the NMDA receptor, reduced the ganglion cell responses to NMDA puffs, and reduced the potassium puff- and light-elicited EPSCs. "
3.	Seizures (Absence Seizure) 01/05/2001 - "Continuous microperfusion of the antagonist for the glycine binding site in NMDA receptors 5,7-dichlorokynurenic acid (100 microM) reversed the effect of both glutamate (1 mM) and glycine (1 mM) and suppressed seizures completely in 90% of the animals. "
4.	Neuralgia (Stump Neuralgia) 06/28/2005 - "L-701,324 (the centrally active antagonist) and 5,7-dichlorokynurenic acid (5,7-DCK, known to have limited central access) were tested after systemic administration in rats in the formalin test and in two models of neuropathic pain. "
5.	Hypoxia (Hypoxemia) 02/14/2000 - "5,7-DCKA and CGP 37849 also blocked the hypoxia/hypoglycaemia-induced suppression of fEPSPs but CGP 37849 (EC50=4.3+/-0.33 microM) was far less potent than against the induction of LTP whilst 5,7-DCKA (EC50=1.47+/-0.04 microM) had similar potency in these two models. " 02/14/2000 - "The calculated relative therapeutic indices (IC50 LTP over EC50 hypoxia/hypoglycaemia) for 5,7-DCKA, CGP 37849, memantine and (+)MK-801 were 1.72, 0.09, 0.82 and 0.24 respectively. "

Related Drugs and Biologics

1.	Glycine (Aminoacetic Acid)
2.	N-Methyl-D-Aspartate Receptors (NMDA Receptors)
3.	Haloperidol (Haldol)
4.	Glutamic Acid (Glutamate)
5.	Dizocilpine Maleate (Dizocilpine)
6.	N-Methylaspartate (NMDA)
7.	Potassium
8.	Memantine (Namenda)
9.	Formaldehyde (Formol)
10.	L 701324